The insider sales are too small to be informative. Monitor for any insider buying or material pipeline catalysts (APEX Phase 2 data) that could move the stock. The strong cash runway and bullish analyst consensus suggest the recent offering was well-received.
APGE drugs
APGE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $78.75entry
- T+1 · 6mo ago −0.61%α +0.04% · $78.27
- T+5 · 6mo ago +5.16%α +3.54% · $82.81
- T+20 · 5mo ago +8.24%α +6.66% · $85.24
- T+60 · 3mo ago +70.86%α +66.01% · $134.55
Price Chart
How similar events traded
Executive Summary
CEO Michael Thomas Henderson sold $1.53M worth of APGE stock on May 13, 2026, and CMO Carl Dambkowski sold $311K on May 6, totaling $1.84M in insider sales. This cluster follows the company's Q1 2026 earnings release (net loss widened to $74.1M) and a $403M public offering. The sales represent ~0.03% of APGE's $6.3B market cap, a trivial amount, and are likely liquidity-driven post-offering rather than signaling bearish conviction.
Key Financial Metrics
Key Facts
- CEO Henderson sold 18,659 shares at $82.05 for $1.53M on May 13, 2026.
- CMO Dambkowski sold 3,700 shares at $83.92 for $311K on May 6, 2026.
- Total insider sales of $1.84M represent ~0.03% of APGE's $6.3B market cap.
- Sales occurred 2-9 days after Q1 2026 earnings (net loss $74.1M, wider than $55.3M YoY) and a $403M public offering.
- APGE has a strong cash position of $1.3B, extending runway into 2029.
- Analyst consensus is 83% bullish (19 Buy/10 Strong Buy, 4 Hold).
Financial Impact
Insider sales of $1.84M are trivial relative to $6.3B market cap (0.03%). No material financial impact.
Risk Factors
- Widening net loss trajectory (Q1 2026 loss of $74.1M vs. $55.3M YoY) could pressure cash burn if pipeline milestones are delayed.
- Potential for further dilutive offerings if cash needs increase beyond 2029 runway.
- Insider selling pattern, while small, may continue post-offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-APGE-1778889642156 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers